Posted on July 4, 2009 by Sitemaster
If a patient is diagnosed with either high-risk prostate cancer that appears to be confined to the prostate or potentially locally advanced disease that may have progressed into nearby pelvic tissues, the question arises whether it is better to simply radiate the prostate alone with curative intent or to radiate both the prostate and the nearby tissues, which is inevitably going to increase the risk for adverse events. … READ MORE …
Filed under: Management, Treatment | Tagged: PORT, prostate only radiotherapy, whole pelvis radiotherapy, WPRT | Leave a Comment »
Posted on July 4, 2009 by Sitemaster
A recent study has assessed the risk of bleeding as a consequence of radiation therapy for localized prostate cancer in men being treated with anticoagulants . … READ MORE …
Filed under: Management, Treatment | Tagged: anticoagulant, bleeding, clopidogrel, EBRT, external beam radiation, risk, warfarin | Leave a Comment »
Posted on July 3, 2009 by Sitemaster
A media release issued last Wednesday from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and based on data presented at the recent annual meeting of the American Society for Clinical Oncology (ASCO), is suggesting that it is possible to predict, with greater accuracy, the long-term risk of metastatic disease in men treated surgically for supposedly localized prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: metastasis, prognosis, surgery | Leave a Comment »
Posted on July 3, 2009 by Sitemaster
It is still not unusual, in large parts of the world, for patients to be diagnosed with prostate cancer and treated with hormone therapy as a first-line treatment or following a period of active surveillance or monitoring — for all sorts of reasons. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: localized, palliation, radiotherapy, symptoms | Leave a Comment »
Posted on July 3, 2009 by Sitemaster
Some years have passed since D’Amico and colleagues developed their risk classification system for newly diagnosed prostate cancer patients which placed any patient with a PSA > 20 ng/ml into the high-risk category. And since the introduction of that classification system, we are aware of limited data on the long-term outcomes of surgical treatment of men who fall into that category. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: "high risk", patients, surgery | Leave a Comment »
Posted on July 2, 2009 by Sitemaster
As mentioned on Tuesday this week, an article and an editorial on prostate cancer screening were just published in CA: A Cancer Journal for Clinicians. Initial media reports on the article and editorial implied that the authors were suggesting that there is no value to testing for prostate cancer. Let us be very clear. This is not what the article or the editorial say at all. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: Prevention, risk, screening, testing | 7 Comments »
Posted on July 2, 2009 by Sitemaster
Today’s news reports discuss such issues as:
- Sextant biopsy in diagnosis of unilateral prostate cancer
- Aggressiveness of prostate cancer in man diagnosed with PSA < 4 ng/ml
- The potential of 3T MRI in prostate cancer prognosis pre-surgery
- Surgical margins and risk for biochemical recurrence post-surgery … READ MORE …
Filed under: Uncategorized | Tagged: 3T MRI, aggressiveness, biopsy, low PSA levels, prognosis, risk, sextant, surgical margins | Leave a Comment »
Posted on July 2, 2009 by Sitemaster
Data have just been published on a series of 172 patients with organ-confined prostate cancer treated with transrectal, whole-gland, high-intensity focused ultrasound (HIFU) between February 1, 2005 and May 15, 2007 at two medical centers in the UK. … READ MORE …
Filed under: Management, Treatment | Tagged: HIFU, high-intensity focused ultrasound | Leave a Comment »
Posted on July 1, 2009 by Sitemaster
A new — but very small and short-term study — has attempted to assess the baseline prevalence of cognitive impairment in older men treated with androgen deprivation therapy (ADT) and changes in cognitive performance over time. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, cognitive, function, hormone, performance, therapy | 1 Comment »
Posted on July 1, 2009 by Sitemaster
In today’s news reports we cover items on:
- Prediction of risk for prostate cancer under-grading based on biopsy data
- The obesity/risk equation in prostate cancer
- Capecitabine + docetaxel in metastatic CRPC … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: biopsy, capecitabine, CRPC, docetaxel, Gleason score, obesity, risk, under-grading | Leave a Comment »
Posted on June 30, 2009 by Sitemaster
In todayas news reports we deal with items about:
- Celecoxib therapy prior to radical prostatectomy for cT1-2 disease
- Sentinel lymph node dissection (again)
- Surgical decompression and spinal reconstruction in man with spinal metastasis … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: surgery, lymph node, dissection, sentinel, cedlecoxib, Celebrax, spinal metastases, decompression | Leave a Comment »
Posted on June 30, 2009 by Sitemaster
An article to be published in the July/August issue of CA: A Cancer Journal for Clinicians, but not yet available on line, as well as the accompanying editorial, is causing a flurry of new, and somewhat misleading, media information about the association between individual testing for risk of prostate cancer and the potential of mass PSA screening to lead to prostate cancer “overdiagnosis.” … READ MORE …
Filed under: Diagnosis, Risk | Tagged: screening | 1 Comment »
Posted on June 27, 2009 by Sitemaster
A recent study from researchers at the University of California, San Francisco and the Dana-Farber Cancer Center is now suggesting that elevated selenium levels in the blood may worsen prostate cancer outcomes in some men who already have the disease. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: risk, selenium, SOD2, superoxide dismutase | 5 Comments »
Posted on June 27, 2009 by Sitemaster
The “Reach Out to Enhance Wellness” (RENEW) trial was initiated as a randomized multi-center, multi-national trial to actually prove something which many would consider to be “obvious”: the idea that lifestyle modification will help cancer survivors to avoid the risks that they are at for second malignancies, other comorbidities, and accelerated functional decline. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: lifestyle, quality of life, survival | Leave a Comment »
Posted on June 27, 2009 by Sitemaster
Today’s news reports deal with such items as:
- Genomic testing for prostate cancer and the value of specific SNPs
- What do pre-treatment MRI/MRSI tests and molecular profiling add to prognostic significance?
- Quality of life following salvage brachytherapy … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: brachytherapy, Diagnosis, genome, MRI, MRSI, prognosis, quality of life, salvage, SNPs | Leave a Comment »
SUPPORT 
Search for new and
ongoing trials on the
CTAG PCa web site
